The COPCOV Trial’s position statement on “A living WHO guideline on drugs to prevent COVID-19.”
Following WHO recommendations against the use of hydroxychloroquine in the prevention of COVID-19, including its use in controlled trials, we are reviewing the guideline and available evidence. We are concerned that this judgement from the authors of the guideline is scientifically unsound.
A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border.
Saito M. et al, (2021), BMC medicine, 19
Equity for excellence in academic institutions: a manifesto for change
Wedekind L. et al, (2021), Wellcome Open Research, 6, 142 - 142
Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
Hamaluba M. et al, (2021), The Lancet. Infectious diseases